Lantheus Holdings, Inc. (LNTH) Company Overview

What does Lantheus Holdings do?

Lantheus Holdings, Inc. is a Nasdaq-listed radiopharmaceutical company focused on diagnostic imaging products that help clinicians detect, characterize, and monitor disease. Its commercial center of gravity is positron emission tomography, or PET, where radioactive tracers are administered to patients and then detected by specialized scanners. The company’s products serve oncology, neurology, and cardiology, with prostate-cancer imaging, amyloid imaging, and ultrasound-enhancing agents forming the current commercial base.

Which products define the company today?

PYLARIFY is an F-18 PSMA PET imaging agent used in prostate cancer and remains the largest product by a wide margin. DEFINITY is an ultrasound-enhancing agent used in echocardiography, providing a more mature and comparatively stable cardiology revenue stream. Neuraceq, acquired with Life Molecular Imaging in 2025, is an amyloid PET imaging agent used in evaluating patients for Alzheimer’s disease and related conditions. The official product portfolio also includes strategic-partnership revenue and investigational imaging agents.

The company describes itself as radiopharmaceutical-focused and organizes its strategic direction around helping clinicians “Find, Fight and Follow” disease. That positioning matters because Lantheus is not simply selling a conventional drug: it coordinates isotope supply, decentralized manufacturing, regulatory approvals, reimbursement, physician adoption, scanner capacity, and time-sensitive distribution.

How does Lantheus make money?

Lantheus earns most of its revenue from product sales. In the quarter ended March 31, 2026, net product revenue was $369.8 million and license-and-royalty revenue was $7.5 million, producing total revenue of $377.3 million. Product economics differ from ordinary pharmaceuticals because many PET tracers have short half-lives and must be manufactured near the patient, creating a network-based operating model.

Why is the manufacturing network economically important?

F-18 tracers decay rapidly, so manufacturing capacity, scheduling, quality control, and delivery reliability are part of the product value proposition. Lantheus relies on a network of PET manufacturing facilities and commercial partners. That network can create barriers to entry, but it also introduces operational dependencies: shortages, facility disruptions, regulatory findings, or scanner bottlenecks can immediately affect sales.

Which revenue stream matters most?

PYLARIFY remains the dominant stream, but the mix is broadening. Neuraceq adds neurology exposure, DEFINITY supplies an established cardiology franchise, and Evergreen adds contract development and manufacturing capabilities. Management’s 2026 strategy emphasizes innovative PET diagnostics while seeking value-maximizing alternatives for radiotherapeutic assets, reducing the near-term breadth of the company’s investment agenda.

What did Lantheus’s latest quarter show?

The first quarter of 2026 showed modest top-line growth but pressure on product economics. Revenue rose 1.2% year over year to $377.3 million. Gross profit declined 2.9% to $230.9 million, while operating income fell 20.3% to $81.3 million. Net income rose to $118.4 million, but that figure benefited from a $59.3 million gain on the sale of the legacy SPECT business and a favorable swing in unrealized equity-investment values. The operating result therefore gives a cleaner picture of the underlying quarter than net income alone.

The Q1 2026 earnings release and the related Form 10-Q show that PYLARIFY sales declined 6.5% to $240.9 million, DEFINITY grew 6.8% to $84.6 million, and Neuraceq contributed $35.4 million with no comparable prior-year amount.

Which strategic turning points shaped Lantheus?

Lantheus’s current model is the result of a long transition from traditional diagnostic imaging agents toward higher-growth PET radiopharmaceuticals. The important history is not the age of the company by itself, but the sequence of portfolio changes that created today’s concentration in prostate-cancer imaging and its newer expansion into neurology.

1. 1956
   The predecessor business began in medical imaging, creating decades of regulatory, manufacturing, and hospital-channel experience.
2. 2015
   Lantheus became a public company, increasing access to capital for portfolio investment and business development.
3. 2021
   FDA approval and commercialization of PYLARIFY transformed the revenue mix toward PSMA PET prostate-cancer imaging.
4. 2022
   The acquisition of Progenics deepened oncology capabilities and supplied important development assets and commercial rights.
5. 2025
   The Evergreen acquisition added radiopharmaceutical development and manufacturing capabilities; Life Molecular Imaging added Neuraceq and a neurology pipeline.
6. 2026
   The SPECT business was sold, and management sharpened the strategic focus on innovative PET radiodiagnostics while evaluating alternatives for radiotherapeutics.

Why did PYLARIFY change the company?

PYLARIFY moved Lantheus from a diversified diagnostic-imaging supplier into a company whose economics are dominated by one fast-growing molecular-imaging category. That created scale, cash flow, and a stronger market position, but also product concentration. In 2025, PYLARIFY generated $989.1 million, or about 64% of total company revenue, even after a 6.5% annual decline.

Why do the 2025 acquisitions matter?

Evergreen gives Lantheus a more direct role in radiopharmaceutical development and production, while Life Molecular Imaging broadens the commercial portfolio into Alzheimer’s disease imaging. Together they make Lantheus less dependent on a single disease area, but they also add integration costs, intangible-asset amortization, regulatory execution, and launch-readiness demands.

What gives Lantheus a competitive advantage?

The moat is a combination of clinical adoption, a distributed manufacturing network, regulatory know-how, reimbursement capability, and established relationships with imaging centers. None of those elements is sufficient alone. The value emerges from coordinating them reliably at national scale.

Where do switching costs come from?

Imaging centers must integrate ordering, scheduling, dose handling, quality procedures, billing, and physician workflows. Once a tracer is embedded in those routines and supported by reliable local supply, switching is not frictionless. Clinical familiarity and interpretation experience also matter, particularly when physicians compare images over time.

Who are the main competitors?

Competition comes from other approved PSMA PET agents, amyloid tracers, ultrasound-enhancing agents, and alternative diagnostic modalities. In prostate imaging, rival tracers and potential new formulations can compete on image quality, availability, economics, and distribution reach. In neurology, Neuraceq competes with other amyloid PET agents, while emerging blood-based biomarkers could alter the testing pathway over time. In cardiology, DEFINITY competes with other ultrasound-enhancing agents and faces normal hospital purchasing pressure.

How financially strong is Lantheus?

Lantheus entered 2026 with meaningful liquidity and strong operating cash generation, but the balance sheet also reflects an acquisition-heavy 2025. Cash and cash equivalents rose from $359.1 million at December 31, 2025 to $498.6 million at March 31, 2026. The company also had access to a $750 million revolving credit facility. Convertible notes had a carrying value of $575.0 million at quarter-end.

What did 2025 establish as the annual baseline?

Full-year 2025 revenue was $1.542 billion, only 0.5% above 2024. Gross profit was $942.0 million, operating income was $310.8 million, and net income was $233.6 million. PYLARIFY revenue fell 6.5% to $989.1 million, while precision-diagnostics revenue grew 12.7% to $493.1 million. The annual pattern therefore showed diversification progress but weaker economics in the dominant product.

The official 2025 Form 10-K and full-year earnings release show that the business remains cash-generative, but future financial strength depends on restoring product-level growth and converting pipeline investment into commercial revenue.

Which pipeline and product launches matter most?

Lantheus’s pipeline is concentrated in imaging agents and selected radiotherapeutic opportunities. The company’s official pipeline includes oncology and neurology candidates at different stages, including MK-6240 for tau imaging in Alzheimer’s disease and NAV-4694 for amyloid imaging.

Why does PYLARIFY TruVu matter?

The FDA approved PYLARIFY TruVu in March 2026, and Lantheus expects a rolling commercial introduction beginning in the fourth quarter of 2026. The new formulation is intended to support technology transfer across the PET manufacturing network and preserve continuity in the franchise. Execution will depend on facility approvals, reimbursement, customer conversion, and supply readiness. The official approval announcement identifies commercialization as a staged process rather than an immediate full-network switch.

How could neurology change the revenue mix?

Neuraceq generated $35.4 million in Q1 2026, already representing 9.4% of quarterly revenue. Growth in Alzheimer’s disease diagnostics could be supported by broader use of disease-modifying therapies that require biomarker confirmation and monitoring. Yet this opportunity is exposed to reimbursement decisions, specialist capacity, competing PET agents, and the emerging role of blood-based tests.

Who owns Lantheus stock, and why does governance matter?

Lantheus has a conventional one-share, one-vote public-company structure rather than founder or family control. The investor base is institutionally concentrated. According to the 2026 proxy statement, BlackRock beneficially owned 13.3%, Vanguard 10.8%, Janus Henderson 8.8%, and Farallon-affiliated entities 8.4%. Directors and executive officers as a group beneficially owned 1.7% as of March 6, 2026.

What does the leadership transition imply?

Mary Anne Heino served as executive chairperson and chief executive officer in the 2026 proxy following Brian Markison’s retirement announcement. Leadership continuity matters because Lantheus is simultaneously integrating two acquisitions, launching products, managing PYLARIFY pricing, and narrowing its strategic focus. The 2026 proxy statement provides the most useful official view of board structure, beneficial ownership, and executive incentives.

What risks could change Lantheus’s outlook?

The largest risk is product concentration. PYLARIFY still supplies nearly two-thirds of revenue, so lower net pricing, market-share losses, reimbursement changes, or manufacturing disruption can outweigh growth elsewhere. Q1 2026 demonstrated this directly: PYLARIFY volume increased, but lower net price contributed to a 6.5% sales decline.

Why can reported earnings be noisy?

Lantheus holds equity investments whose market values flow through earnings, and it records acquisition-related amortization, contingent-consideration changes, and transaction costs. Asset sales can also create large gains. Analysts therefore need to reconcile GAAP net income with operating income and cash flow rather than relying on EPS in isolation.

What is the key strategic execution risk?

The company must execute several transitions at once: defend the PYLARIFY franchise, migrate customers to TruVu, grow Neuraceq, integrate Evergreen and Life Molecular Imaging, advance late-stage assets, and decide how to monetize or partner radiotherapeutic programs. A failure in one area may be manageable; simultaneous setbacks would pressure growth, margin, and confidence in capital allocation.

Which KPIs and valuation drivers matter most?

For a discounted cash flow analysis, Lantheus should not be modeled as a generic pharmaceutical company. The most important drivers are PYLARIFY price and volume, the pace of neurology growth, gross-margin recovery, commercial launch spending, pipeline success probabilities, and the reinvestment needed to support a decentralized radiopharmaceutical network.

How should a DCF treat the business?

Near-term revenue should be built product by product rather than with one company-wide growth rate. PYLARIFY requires explicit assumptions for price, volume, share, and the TruVu transition. DEFINITY can be modeled as a steadier franchise. Neuraceq and pipeline assets need scenario-weighted adoption curves. Gross margin should reflect product mix, amortization, manufacturing economics, and rebates. Free cash flow should begin with operating cash flow, subtract capital expenditures, and then be adjusted for unusual acquisition, integration, or divestiture items.

What is the key takeaway from Lantheus analysis?

Lantheus is important because it built one of the most commercially significant radiopharmaceutical imaging franchises in the United States and used that platform to expand into neurology and broader PET diagnostics. Its strengths are a scaled manufacturing and distribution network, established clinical adoption, regulatory experience, strong cash generation, and a portfolio that now spans oncology, cardiology, and neurology.

The central weakness is equally clear: PYLARIFY remains too large for softness in price or share to be easily absorbed. The first quarter of 2026 captured that tension. Revenue grew modestly, cash flow remained healthy, and Neuraceq added diversification, yet gross profit and operating income fell because the dominant product faced lower net pricing and the organization carried higher commercialization and integration costs.

For students and investors, the company is a useful case study in how distribution infrastructure, reimbursement, regulatory approval, and clinical workflow combine to create a moat in healthcare. It is also a reminder that a powerful market position can coexist with concentration risk. The next several reporting periods should be judged by product-level growth, operating margin, cash conversion, and concrete launch milestones rather than by headline EPS alone.